In recent years, it has been found that elevated levels of monomeric prolactin (hyperprolactinemia) [14] and excess of high molecular weight prolactin (macroprolactinemia) [15] attenuate the pleiotropic effects of atorvastatin. The gene discussed is PRL; the disease is hyperprolactinemia.